URB597
 | |
| Names | |
|---|---|
| IUPAC name
[3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate | |
| Identifiers | |
546141-08-6  | |
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL184238  |
| ChemSpider | 1156960 |
| ECHA InfoCard | 100.164.994 |
| 4339 | |
| MeSH | URB597 |
| PubChem | 1383884 |
| |
| |
| Properties | |
| C20H22N2O3 | |
| Molar mass | 338.41 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
URB597 (KDS-4103) is a relatively selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH).[1][2] FAAH is the primary degradatory enzyme for the endocannabinoid anandamide and, as such, inhibition of FAAH leads to an accumulation of anandamide in the CNS and periphery where it activates cannabinoid receptors. URB597 has been found to elevate anandamide levels and have activity against neuropathic pain in a mouse model.[3]
URB597 was at one point being developed by Kadmus Pharmaceuticals, Inc. for clinical trials in humans.[4]
See also
References
- ↑ Mor, Marco; Rivara, S; Lodola, A; Plazzi, PV; Tarzia, G; Duranti, A; Tontini, A; Piersanti, G; Kathuria, S; Piomelli, Daniele (2004). "Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies". J Med Chem. 47 (21): 4998–5008. doi:10.1021/jm031140x. PMID 15456244.
- ↑ Alexander, JP; Cravatt, BF (2005). "Mechanism of Carbamate Inactivation of FAAH: Implications for the Design of Covalent Inhibitors and In Vivo Functional Probes for Enzymes". Chem Biol. 12 (11): 1179–87. doi:10.1016/j.chembiol.2005.08.011. PMC 1994809
. PMID 16298297. - ↑ Russo, R; Loverme, J; La Rana, G; Compton, TR; Parrott, J; Duranti, A; Tontini, A; Mor, M; Tarzia, G; Calignano, A.; Piomelli, D. (2007). "The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice". J Pharmacol Exp Ther. 322 (1): 236–42. doi:10.1124/jpet.107.119941. PMID 17412883.
- ↑ Kadmus Pharmaceuticals official website Archived December 19, 2005, at the Wayback Machine.
External links
This article is issued from Wikipedia - version of the 11/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.